Gerresheimer (ETR:GXI) Trading Down 5.4% - Here's Why

Key Points

• Gerresheimer shares fell 5.4% on Tuesday to about €19.46 (intraday low €19.15) on roughly 144,029 shares traded—about 2% above the average—after a prior close of €20.58.
• The company shows weak liquidity (quick ratio 0.40, current ratio 0.98) and very high leverage (debt-to-equity 164.82), with a market cap of $666.25M, a P/E of 5.83 and 50-/200-day moving averages of €21.21 and €26.39 indicating a downtrend.
• Gerresheimer manufactures medicine packaging and drug-delivery devices—such as prefillable syringes, vials, inhalers and autoinjectors—across its Plastics & Devices, Primary Packaging Glass and Advanced Technologies divisions.

Gerresheimer AG (ETR:GXI - )'s share price was down 5.4% during trading on Tuesday . The company traded as low as €19.15 and last traded at €19.46. Approximately 144,029 shares changed hands during trading, an increase of 2% from the average daily volume of 140,925 shares. The stock had previously closed at €20.58.

Gerresheimer Stock Down 5.4%

The company has a quick ratio of 0.40, a current ratio of 0.98 and a debt-to-equity ratio of 164.82. The firm has a 50 day simple moving average of €21.21 and a 200-day simple moving average of €26.39. The stock has a market cap of $666.25 million, a P/E ratio of 5.83, a price-to-earnings-growth ratio of 0.82 and a beta of 0.57.

About Gerresheimer

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.